Improving Myeloma Outcomes

Ajai Chari, MD

Video Categories: Hematological Malignancies

Dr. Ajai Chari discusses the ultimate goal of improving therapy for myeloma patients. He mentions the COMPASS study, which is working to collect a database of clinical and scientific information on 1000 patients. In the interim, there are some clues, such as an understanding of certain high-molecular-risk patients and some evidence of certain subgroups that have increased response to some new drugs. This allows physicians to be more selective for those who are most likely to benefit from certain therapies.
December 18, 2018

Financial Constraints to Molecular Biomarker Testing

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.

April 14, 2015

Unclear Diagnoses in Patients with Metastatic Disease

Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.